AstraZeneca teams up with Abbott on Crestor co-promote

Share this article:
AstraZeneca teams up with Abbott on Crestor co-promote
AstraZeneca teams up with Abbott on Crestor co-promote
Seeking to increase its share of voice without beefing up its sales force, AstraZeneca is partnering with Abbott on a co-promotion of Crestor in the US.

AstraZeneca spokeswoman Donna Huang said the move is a response, in part, to increased interest in the drug among physicians since it received an indication for use in slowing the progress of atherosclerosis last November.

“For us, it's about knowing that we're meeting that need with extra share of voice, without increasing the size of our sales force,” said Huang. “That creates flexibility for us in the future to reallocate resources when we have emerging compounds that we're launching.”

US net sales of the drug for the second quarter were up 17% over Q2 2007 to $415 million. Crestor has doubtless benefited from the uncertainty surrounding rival Merck/Schering-Plough's Vytorin, which has stumbled since its ENHANCE trial showed no benefit in fighting atherosclerosis. In February, AstraZeneca launched ads touting the findings of its METEOR study, which showed Crestor to be effective in slowing atherosclerosis. The company has also run an unbranded atherosclerosis awareness campaign dubbed "Us Against Athero."

The deal gives Abbott the non-exclusive right to promote Crestor alongside AstraZeneca in the US, excluding Puerto Rico. The companies declined to comment on the financial terms of the deal or the size of the sales forces involved. AstraZeneca's US sales force numbers around 5.500 overall.

It's the second time the two firms have teamed up on lipid drugs – under a 2006 agreement, they're partnering on a combination of Crestor and Abbott's TriLipix, a developmental fibrate. Abbott expects an FDA decision on TriLipix before the end of the year, and the companies plan to submit an NDA for the combo in the second half of 2009.

Abbott also markets HDL-raising Niaspan, triglyceride-lowering TriCor and Niaspan/simvastatin combo Simcor.

Crestor is indicated for use as an adjunct to diet in treating lipid disorders including primary hyperlipidemia, mixed dyslipidemia and isolated hypertriglyceridemia, as well as for slowing the progression of atherosclerosis in adult patients.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Channel

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...